Alnylam Pharma (ALNY) Misses Q4 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Piper Jaffray Cuts PT on Alnylam (ALNY) by 45%; Keep 'Overweight'
February 12, 2016 8:26 AM ESTPiper Jaffray analyst, Edward Tenthoff, cut his Alnylam Pharmaceuticals (NASDAQ: ALNY) price target to $102 from $184 which still represents 79% upside from current levels. No change to Overweight rating.
Alnylam ended 2015 with cash of $1.28 billion and guided to end 2016 with >$850 million including a $100 million investment in an RNAi manufacturing facility. The company recently completed enrollment of >200 familial amyloidotic polyneuropathy (FAP) patients in the Phase III APOLLO trial setting up top-line data in 2H:17 and a potential launch in 2018. Alnylam is advancing and expanding its... More
